To survive, cancer cells are subjected to various internal and external adverse factors,
including genetic mutations, hypoxia, nutritional deficiencies, and drug toxicity. All of these …

Cancer cells must overcome a variety of external and internal stresses to survive and
proliferate. These unfavorable conditions include the accumulation of mutations, nutrient …

Purpose: In ALK-rearranged non–small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …

Proteasome machinery is a major proteostasis control system in human cells, actively
compensated upon its inhibition. To understand this compensation, we compared global …

Simple Summary Advances in treatment, especially with novel drugs, have dramatically
improved the survival of multiple myeloma (MM) patients recently. However, frequent …

Simple Summary Blood malignancies account for 6.9% of all cancer deaths. Inositol-
requiring enzyme 1 alpha (IRE1α), a part of the unfolded protein response (UPR), has been …

Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …

Synthetic oleanane triterpenoids (SOTs) are small molecules with broad anticancer
properties. A recently developed SOT, 1‐[2‐cyano‐3, 12‐dioxooleana‐1, 9 (11)‐dien‐28 …

Bortezomib (BTZ), a selective proteasome inhibitor, exhibits a significant efficacy in the
therapy of multiple myeloma (MM) partly through triggering endoplasmic reticulum (ER) …

Antibody secreting plasma cell plays an indispensable role in humoral immunity. As
activated B cell undergoes germinal center reaction and develops into plasma cell, it …